Dihydroartemisinin- piperaquine dispersible

DHA-PQP dispersible
Alfasigma
Asexual blood stages
Paediatric formulation
No progress report in last two years
3-day cure, artemisinin-based combination therapies (TPP-1)

Dihydroartemisinin- piperaquine dispersible

Product development
-
Patient confirmatory
Product vision
  • 3-day cure, artemisinin-based combination therapy¬†
Dosing
  • Once-daily for 3 days

Efficacy
  • Efficacy in adults established

  • Pharmacokinetic bridging strategy to establish paediatric dose

Key features
  • Anticipated comparatively long post-treatment protection

Challenges
  • Potential cardiac monitoring restrictions
  • Confirmed piperaquine resistance in Greater Mekong Sub-region¬†
Status
  • Pharmacokinetic studies in children completed
  • Dossier under development for submission to European Medicines Agency (EMA)
Next milestone
  • Submission to EMA

Project Director
  • Adam Aspinall